John Bennett, a partner in Goodwin’s IP Litigation Group, focuses his practice on intellectual property, with a particular emphasis on patent litigation, trade secret and copyright disputes. He has extensive experience in pharmaceutical patent litigation under the Hatch-Waxman Act, from initial counseling through trial and appeal. He also has experience representing clients in patent litigation concerning a variety of other technologies including medical devices, Internet content delivery systems and sports equipment.

Mr. Bennett also routinely performs pro bono work and his engagements have included representation of a Mariel Cuban refugee detained by the federal government for more than 14 years prior to his release on parole in 2004.




Mr. Bennett’s recent engagements include:

  • Lead counsel for Fresenius Kabi USA, LLC and USV North America as generic defendants in patent litigation concerning the bone disorder treatment Zometa® pending before Judge Susan Davis Wigenton in the U.S. District Court, District of New Jersey.
  • Trial Counsel for Fresenius Kabi USA, LLC in patent litigation concerning its branded parenteral anesthetic, Diprivan®, pending before Judge Richard G. Andrews in the U.S. District Court, District of Delaware.
  • Trial counsel for Teva Pharmaceuticals in patent litigation concerning its branded treatment for idiopathic Parkinson’s disease, Azilect®. Teva prevailed after a May 2013 bench trial before Judge Claire C. Cecchi in the U.S. District Court, District of New Jersey.  Judge Cecchi ruled that Teva’s patent covering Azilect® had been infringed and was not invalid.
  • Trial and appellate counsel for Teva Pharmaceuticals in patent litigation concerning its blockbuster innovative treatment for multiple sclerosis, Copaxone®, pending in the U.S. District Court, Southern District of New York. Teva prevailed on all nine patents asserted at the trial court in June 2012 and the Federal Circuit affirmed the judgment in 2013 as to four of the asserted patents.
  • Trial and appellate counsel for Teva Pharmaceuticals as a generic defendant in patent litigation concerning Sanofi-Aventis’s blockbuster treatment for deep vein thrombosis, Lovenox®. Teva prevailed after a bench trial in the U.S. District Court, Central District of California before Judge Mariana R. Pfaelzer, resulting in a ruling that Sanofi’s Orange Book patent covering Lovenox® was unenforceable due to inequitable conduct. This ruling was affirmed by the Federal Circuit in 2008.
Professional Activities

Mr. Bennett is a member of the Boston and Massachusetts Bar Associations.

Professional Experience

Prior to joining Goodwin, Mr. Bennett was an associate with Palmer & Dodge in Boston, where his practice focused on intellectual property matters.

In The News

In den Nachrichten






J.D., 2000
Boston College Law School
B.A., 1996
Dartmouth College

(cum laude with high honors)





U.S. Court of Appeals for the Federal Circuit
U.S. Court of Appeals for the Fifth Circuit
U.S. Court of Appeals for the Tenth Circuit
U.S. District Court for the District of Massachusetts
Get In Touch
In Kontakt kommen
Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.
Unsere Kunden verlassen sich auf uns für erstklassige Beratungsdienste, beraten über komplexe Transaktionsarbeiten und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Industrie, verwenden wir eine kooperative, interdisziplinäre Ansatz zur Lösung unserer Kunden am schwierigsten Fragen. Um mehr zu erfahren, kontaktieren Sie uns bitte.


Search Other Lawyers
Suche Andere Rechtsanwälte